CN109364092B - Application of solanine - Google Patents
Application of solanine Download PDFInfo
- Publication number
- CN109364092B CN109364092B CN201811605334.6A CN201811605334A CN109364092B CN 109364092 B CN109364092 B CN 109364092B CN 201811605334 A CN201811605334 A CN 201811605334A CN 109364092 B CN109364092 B CN 109364092B
- Authority
- CN
- China
- Prior art keywords
- human
- cancer cells
- rhinacine
- cell carcinoma
- squamous cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of solanine. The rhinacanthus nasutus whole herb medicine is distributed in Guangxi Guigang, Yulin, Fangcheng and Wuming places, and is used for treating acute and chronic bronchitis, tuberculosis, cirrhosis, nephritic edema, furuncle, acute mastitis, skin eczema, traumatic hemorrhage and other diseases in traditional Chinese medicine. The agrimonine is a chemical component separated from the agrimony. The invention tests the proliferation inhibition activity of the rhinacine on human lung adenocarcinoma cells H2228, human bladder cancer cells T24, human liver cancer cells SMMC-7721, human breast cancer cells MCF-7, human gastric cancer cells MGC-803 and human oral squamous cell carcinoma Tca8113, finds that the rhinacine has excellent inhibition effect on human bladder cancer cells T24 and human oral squamous cell carcinoma Tca8113, and has no obvious inhibition effect on other tested tumor cells, therefore, the rhinacine can be used for preparing the medicine for treating bladder cancer or oral squamous cell carcinoma.
Description
Technical Field
The invention belongs to the field of medicines, relates to new application of a known natural product, and particularly relates to new application of solanine.
Background
The Argyreiaaaceta herbal medicine is recorded in Guangxi medical plant records and distributed in Guangxi Guigang, Yulin, City-defense Port, Wuming and other places, and is used for treating acute and chronic bronchitis, phthisis, cirrhosis, nephritic edema, furuncle, acute mastitis, skin eczema, traumatic hemorrhage and other diseases in traditional Chinese medicine. The rhinacine is a chemical component (ruru mei, 1 new alkaloid in rhinacanthus nasutus, 49 th vol., 15 th, 2018 th month, Chinese herbal medicine, etc.) separated from rhinacanthus nasutus.
At present, no report of antitumor activity of the rhinacanthin is found.
Disclosure of Invention
The invention aims to provide a new application of solanine.
The technical scheme for realizing the aim of the invention is as follows:
application of rhinacine in preparing medicine for treating bladder cancer is provided.
A pharmaceutical preparation for treating bladder cancer is prepared from an active ingredient and pharmaceutically acceptable auxiliary materials into a pharmaceutically acceptable dosage form, wherein the active ingredient is solanine.
Further, the auxiliary material is a solid, semi-solid or liquid auxiliary material.
Further, the dosage form is preferably tablet, capsule, injection.
Application of rhinacine in preparing medicine for treating oral squamous cell carcinoma is provided.
A pharmaceutical preparation for treating oral squamous cell carcinoma is prepared into a pharmaceutically acceptable dosage form by active ingredients and pharmaceutically acceptable auxiliary materials, wherein the active ingredients are rhinacine.
Further, the auxiliary material is a solid, semi-solid or liquid auxiliary material.
Further, the dosage form is preferably tablet, capsule, injection.
The invention has the outstanding advantages that:
the invention tests the proliferation inhibition activity of the rhinacine on human lung adenocarcinoma cells H2228, human bladder cancer cells T24, human liver cancer cells SMMC-7721, human breast cancer cells MCF-7, human gastric cancer cells MGC-803 and human oral squamous cell carcinoma Tca8113, finds that the rhinacine has excellent inhibition effect on human bladder cancer cells T24 and human oral squamous cell carcinoma Tca8113, and has no obvious inhibition effect on other tested tumor cells, therefore, the rhinacine can be used for preparing the medicine for treating bladder cancer or oral squamous cell carcinoma.
Drawings
FIG. 1 shows the IC50 values of rhinacine for inhibition of proliferation of individual cancer cells.
Detailed Description
The following detailed description of the present invention is provided in connection with the examples, and for reasons of brevity, the description of the experimental procedures is not intended to be exhaustive, and all parts not specifically described in the experiments are routine procedures well known to those skilled in the art.
First, experimental material
Human lung adenocarcinoma cell H2228, human bladder cancer cell T24, human liver cancer cell SMMC-7721, human breast cancer cell MCF-7, human gastric cancer cell MGC-803, and human oral squamous cell carcinoma Tca8113 were cultured with RPMI-1640 containing 10% fetal bovine serum at 37 deg.C and 5% CO respectively2And (4) performing conventional culture in a cell culture box, and selecting cells in a logarithmic growth phase in an experiment.
The rhinacine is prepared by self, and the purity is more than 98%.
RPMI-1640 medium, fetal bovine serum was purchased from Gibco.
Second, Experimental methods
The method adopts an MTT method to test the proliferation inhibition effect of the rhinacine on each cancer cell, and evaluates the anticancer effect of the rhinacine according to the IC50 value of the proliferation inhibition activity of the rhinacine on each cancer cell, and comprises the following specific steps: inoculating each cancer cell into 96-well plate containing RPMI-1640+ 10% fetal bovine serum culture medium, and culturing at 37 deg.C with 5% CO2Culturing for 24h under the condition, adding the gradient concentration rhinacanthin diluted by the culture medium into a culture plate and processing the mixture with a blank control for 72h, adding 20 mu L of MTT reagent with the concentration of 5mg/mL into each well, continuing culturing for 4h, discarding supernatant, adding 150 mu L of LDMSO into each well, shaking for dissolving, measuring the absorbance value (OD570) under the wavelength of 570nm by using a microplate reader, calculating the inhibition rate of the rhinacanthin on each cancer cell according to the following formula, and obtaining the IC50 value by Graphpad fitting.
The inhibition rate (%) was (blank OD 570-experiment OD 570)/blank OD 570X 100%
Third, experimental results
The IC50 values for the inhibition of proliferation of individual cancer cells by rhinacine are shown in table 1 and fig. 1.
TABLE 1 IC50 values for rhinacine inhibition of proliferation of individual cancer cells
The experimental results show that the agrimonine has excellent inhibition effect on human bladder cancer cell T24 and human oral squamous cell carcinoma Tca8113, and has no obvious inhibition effect on other tested tumor cells, so the agrimonine can be used for preparing the medicines for treating bladder cancer or oral squamous cell carcinoma.
The foregoing embodiments are provided to illustrate the present invention more fully, but those skilled in the art will appreciate that the scope of the present invention should not be limited to the specific embodiments described above.
Claims (1)
1. Application of rhinacine in preparing medicine for treating bladder cancer is provided.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811605334.6A CN109364092B (en) | 2018-12-26 | 2018-12-26 | Application of solanine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811605334.6A CN109364092B (en) | 2018-12-26 | 2018-12-26 | Application of solanine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109364092A CN109364092A (en) | 2019-02-22 |
| CN109364092B true CN109364092B (en) | 2020-12-11 |
Family
ID=65371851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811605334.6A Active CN109364092B (en) | 2018-12-26 | 2018-12-26 | Application of solanine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109364092B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101818084B1 (en) * | 2015-04-14 | 2018-01-15 | 대구가톨릭대학교산학협력단 | A composition comprising extract of Lycopodiella cernua or compound isolated therefrom for preventing or treating of Alzheimer disease-Ⅱ |
| CN107513084B (en) * | 2017-08-29 | 2020-06-12 | 广西中医药大学 | Erythrine, its extraction method and application |
-
2018
- 2018-12-26 CN CN201811605334.6A patent/CN109364092B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109364092A (en) | 2019-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109010618B (en) | Traditional Chinese medicine composition with anti-tumor effect and preparation method and application thereof | |
| CN108912086B (en) | Active flavonoid compound and preparation method and application thereof | |
| CN109364092B (en) | Application of solanine | |
| CN102731276A (en) | Diterpene compound possessing antitumor activity, preparation method thereof and application thereof | |
| CN109432118B (en) | Application of solanine in biological medicine | |
| CN102267891B (en) | Novel triterpenoid compound and preparation method thereof | |
| CN103893412B (en) | A kind of antitumor beautyberry extract and its production and use | |
| CN108796022A (en) | The preparation method and application of Saikogenin A and D | |
| CN105399794A (en) | Fructus momordicae triterpene saponin and salt thereof, preparation method and applications of fructus momordicae triterpene saponin and salt thereof, and pharmaceutical composition containing fructus momordicae triterpene saponin and salt thereof | |
| CN102247357B (en) | Application of uvarilactam and aristololactam BI in preparation of anticancer medicaments | |
| CN113214214B (en) | Preparation method and application of terpenoid in Atractylodes lancea | |
| CN108836982A (en) | A kind of toad skin active component and preparation method thereof | |
| CN105801634B (en) | A kind of preparation method and application of straight chain alcohol glycoside compound in green peel of walnut | |
| CN106580937B (en) | The preparation method of euphorbia ebiacteolata Hayata element A and its preparing the application in breast cancer medicines | |
| CN103833823A (en) | Diterpene dimer compounds and pharmaceutical compositions and preparation method and application thereof | |
| CN110522776B (en) | Preparation method and application of anti-tumor effective part in hibiscus syriacus | |
| CN103191143A (en) | New application of cardiac glycoside compound | |
| CN113620912A (en) | Furanone compound and preparation method and application thereof | |
| CN113801000A (en) | Compound with anti-tumor activity and preparation method and application thereof | |
| CN101062045B (en) | Use of triterpene saponin compounds in preparing tumor medicine | |
| CN109498624B (en) | Anticancer medical application of thiazoline derivative | |
| CN109364081B (en) | Application of pyrimidine derivative in preparation of medicine for treating thyroid cancer | |
| CN109432095B (en) | Medical application of thiazoline derivative | |
| CN109705183A (en) | Smelly seven secondary metabolites and its pharmaceutical composition and preparation method and its application | |
| TW202017578A (en) | Preparation method and pharmaceutical composition for the extarct and composition of antrodia cinnamomea. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20201125 Address after: Room 507-508, Kezheng building, No.16, South Tiancheng Road, high speed rail new town, Xiangcheng District, Suzhou City, Jiangsu Province Applicant after: Suzhou juice Network Information Technology Co., Ltd Address before: 211198 No. 18 Zhilan Road, Science Park, Jiangning District, Nanjing City, Jiangsu Province Applicant before: NANJING GAISIFU MEDICAL TECHNOLOGY Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |